Physician profile
Sean Leoni
NPI 1669544052
$6,022.71
in general payments reported to CMS, 2019-2025
28 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $474 · 2021: $683 · 2022: $1,305 · 2023: $900 · 2024: $623 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.41 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,354.76 | 2022-2025 | Dupixent |
| Apyx Medical Corporation | $879.39 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $869.06 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $429.39 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $352.83 | 2019-2024 | Repatha, Otezla, Tezspire |
| Abbott Laboratories | $319.44 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $278.51 | 2023-2025 | Breztri, Fasenra, Farxiga |
| Arbor Pharmaceuticals, INC. | $200.63 | 2019-2021 | |
| Merz North America, INC. | $190.52 | 2019 | |
| Amarin Pharma, INC. | $155.53 | 2020-2022 | |
| Lilly USA, LLC | $149.42 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.46 | 2020-2025 | Jardiance |
| Abbvie INC. | $101.54 | 2021-2025 | |
| Genzyme Corporation | $97.30 | 2023 | |
| Janssen Pharmaceuticals, INC | $93.27 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $82.63 | 2023-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $67.89 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $50.49 | 2021 | |
| Mannkind Corporation | $40.47 | 2019-2020 | |
| Philips North America LLC | $39.13 | 2022-2023 | |
| Eisai INC. | $23.88 | 2020 | |
| Allergan, INC. | $23.76 | 2020 | |
| Optinose US, INC. | $22.72 | 2022 | |
| Tolmar, INC. | $22.36 | 2025 | Jatenzo |
| Azurity Pharmaceuticals, INC. | $20.23 | 2023 | Edarbi |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Pfizer INC. | $17.93 | 2021 | |
| Ermi LLC | $17.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Leoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.